Shattuck Labs, Inc.

NasdaqGS:STTK Stock Report

Market Cap: US$622.3m

Shattuck Labs Balance Sheet Health

Financial Health criteria checks 6/6

Shattuck Labs has a total shareholder equity of $211.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $220.7M and $9.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$208.30m
EquityUS$211.14m
Total liabilitiesUS$9.53m
Total assetsUS$220.67m

Recent financial health updates

Analysis Article • May 18

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Shattuck Labs...
Analysis Article • Oct 02

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jun 15

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 28

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 09

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Nov 23

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Seeking Alpha • Jun 10

Shattuck Labs: "Hold" On Phase 1  SL-325 Data And Next Stage Of Development

Summary Shattuck Labs (STTK) maintains a 'Hold' rating as SL-325 advances with promising phase 1 immunogenicity and PK data in healthy volunteers. SL-325 demonstrated a best-in-mechanism immunogenicity profile, with only 3.7% of subjects developing antidrug antibodies and durable TL1A inhibition for over 3 months. Phase 2b RECEPTIVE-CD1 trial for moderate-to-severe Crohn's Disease is set to initiate in Q3 2026, with 12-week induction data expected in H1 2028. STTK's cash position, including warrant exercises, is sufficient to fund operations into 2029, minimizing near-term dilution risk. Read the full article on Seeking Alpha
Analysis Article • May 18

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Shattuck Labs...
Analysis Article • Oct 02

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jun 15

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 28

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 09

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Nov 23

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

Shattuck Labs press release (NASDAQ:STTK): Q2 GAAP EPS of -$0.65 misses by $0.06. As of June 30, 2022, cash and cash equivalents and short-term investments were $214.2 million, as compared to $268.8 million as of December 31, 2021.
Analysis Article • Jul 26

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 18

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Shattuck Labs, Inc. ( NASDAQ:STTK ) just released its latest annual results and things are looking bullish. The results...

Financial Position Analysis

Short Term Liabilities: STTK's short term assets ($213.3M) exceed its short term liabilities ($7.7M).

Long Term Liabilities: STTK's short term assets ($213.3M) exceed its long term liabilities ($1.8M).

Debt to Equity History and Analysis

Debt Level: STTK is debt free.

Reducing Debt: STTK has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STTK has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: STTK has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 0.6% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 09:02
End of Day Share Price 2026/09/15 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shattuck Labs, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc
Joseph PantginisH.C. Wainwright & Co.